The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Preoperative Multimodality Therapy Improves Disease-Free Survival in Patients With Carcinoma of the Rectum: NSABP R-03
Open accessAbstract
Purpose: Although chemoradiotherapy plus resection is considered standard treatment for operable rectal carcinoma, the optimal time to administer this therapy is not clear. The NSABP R-03 (National Surgical Adjuvant Breast and Bowel Project R-03) trial compared neoadjuvant versus adjuvant chemoradiotherapy in the treatment of locally advanced rectal carcinoma. Patients and Methods: Patients with clinical T3 or T4 or node-positive rectal cancer were randomly assigned to preoperative or postoperative chemoradiotherapy. Chemotherapy consisted of fluorouracil and leucovorin with 45 Gy in 25 fractions with a 5.40-Gy boost within the original margins of treatment. In the preoperative group, surgery was performed within 8 weeks after completion of radiotherapy. In the postoperative group, chemotherapy began after recovery from surgery but no later than 4 weeks after surgery. The primary end points were disease-free survival (DFS) and overall survival (OS). Results: From August 1993 to June 1999, 267 patients were randomly assigned to NSABP R-03. The intended sample size was 900 patients. Excluding 11 ineligible and two eligible patients without follow-up data, the analysis used data on 123 patients randomly assigned to preoperative and 131 to postoperative chemoradiotherapy. Surviving patients were observed for a median of 8.4 years. The 5-year DFS for preoperative patients was 64.7% v 53.4% for postoperative patients (P = .011). The 5-year OS for preoperative patients was 74.5% v 65.6% for postoperative patients (P = .065). A complete pathologic response was achieved in 15% of preoperative patients. No preoperative patient with a complete pathologic response has had a recurrence. Conclusion: Preoperative chemoradiotherapy, compared with postoperative chemoradiotherapy, significantly improved DFS and showed a trend toward improved OS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040694 · Cited by 6,050
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
Kapiteijn, E., Marijnen, C. A. M., Nagtegaal, I. D., Putter, H., Steup, W. H., Wiggers, T., Rutten, H. J. T., Pahlman, L., Glimelius, B., van Krieken, J. H. J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010580 · Cited by 4,205
Effective Surgical Adjuvant Therapy for High-Risk Rectal Carcinoma
Krook, J. E., Moertel, C. G., Gunderson, L. L., Wieand, H. S., Collins, R. T., Beart, R. W., Kubista, T. P., Poon, M. A., Meyers, W. C., Mailliard, J. A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103143241101 · Cited by 1,879
Gérard, J.-P., Conroy, T., Bonnetain, F., Bouché, O., Chapet, O., Closon-Dejardin, M.-T., Untereiner, M., Leduc, B., Francois, É., Maurel, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7629 · Cited by 1,731 · cited 1×
“Fédération Francophone de Cancérologie Digestive in France (FFCD) compared the combination of preoperative chemotherapy (fluorouracil and leucovorin) and radiotherapy versus preoperative radiotherapy alone, with all patients receiving postoperative chemotherapy.(8) The administration of postoperative chemotherapy redu…”
BackgroundPathological features of rectal cancer after preoperative radiochemotherapy
Dworak, O., Keilholz, L., & Hoffmann, A. (1997) · International Journal of Colorectal Disease · doi:10.1007/s003840050072 · Cited by 1,338
Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal Cancer
Rödel, C., Martus, P., Papadoupolos, T., Füzesi, L., Klimpfinger, M., Fietkau, R., Liersch, T., Hohenberger, W., Raab, R., Sauer, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.1329 · Cited by 1,215
(2001) · The Lancet · doi:10.1016/s0140-6736(01)06409-1 · Cited by 870
Preoperative Radiotherapy for Resectable Rectal Cancer: A Meta-analysis
Cammà, C., Giunta, M., Fiorica, F., Pagliaro, L., Craxì, A., & Cottone, M. (2000) · JAMA · doi:10.1001/jama.284.8.1008 · Cited by 754 · cited 1×
“Radiotherapy and surgical resection are standard components of therapy for patients with stage II/III carcinoma of the rectum.(1,2) Numerous randomized trials have investigated the impact of dose modifications and preoperative/postoperative administration in an effort to improve safety without compromising effectivene…”
BackgroundBosset, J.-F., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., Briffaux, A., & Collette, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.113 · Cited by 594
Wolmark, N. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.388 · Cited by 530
Self-citationGaynor, J. J., Feuer, E. J., Tan, C. C., Wu, D. H., Little, C. R., Straus, D. J., Clarkson, B. D., & Brennan, M. F. (1993) · Journal of the American Statistical Association · doi:10.1080/01621459.1993.10476289 · Cited by 483
Vecchio, F. M., Valentini, V., Minsky, B. D., Padula, G. D. A., Venkatraman, E. S., Balducci, M., Miccichè, F., Ricci, R., Morganti, A. G., Gambacorta, M. A., et al. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.11.017 · Cited by 423
Kaminsky-Forrett, M.-C., Conroy, T., Luporsi, E., Peiffert, D., Lapeyre, M., Boissel, P., Guillemin, F., & Bey, P. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00345-9 · Cited by 201
Allocation of patients to treatment groups in a controlled clinical study
White, S. J., & Freedman, L. S. (1978) · British Journal of Cancer · doi:10.1038/bjc.1978.124 · Cited by 191
Bosset, J.-F., Calais, G., Mineur, L., Maingon, P., Radošević-Jelić, L., Daban, A., Bardet, É., Beny, A., Ollier, J., & Collette, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3505 · Cited by 70
Cited by
Sauer, R., Liersch, T., Merkel, S., Fietkau, R., Hohenberger, W., Hess, C., Becker, H., Raab, H.-R., Villanueva, M.-T., Witzigmann, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.1836 · Cited by 2,095
Maas, M., Nelemans, P. J., Valentini, V., Das, P., Rödel, C., Kuo, L.-J., Calvo, F. A., García-Aguilar, J., Glynne-Jones, R., Haustermans, K., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70172-8 · Cited by 1,945
Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510
Rödel, C., Liersch, T., Becker, H., Fietkau, R., Hohenberger, W., Hothorn, T., Graeven, U., Arnold, D., Lang-Welzenbach, M., Raab, H.-R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70187-0 · Cited by 696
Martin, S. T., Heneghan, H. M., & Winter, D. C. (2012) · British Journal of Surgery · doi:10.1002/bjs.8702 · Cited by 637
Metadata
- Authors
- Roh, M. S., Colangelo, L. H., O'Connell, M. J., Yothers, G., Deutsch, M., Allegra, C. J., Kahlenberg, M. S., Baez-Diaz, L., Ursiny, C. S., Petrelli, N. J., & Wolmark, N.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-11-01
- Volume
- 27
- Issue
- 31
- Pages
- 5124-5130
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2124297369
- Cited by
- 933
- References
- 15
- FWCI
- 25.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.